

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Ignacio Jose Ezquerro SAENZ, et al Serial No.: 09/831,253 Group No.: 1711

Filed: June 27, 2001 Examiner.: Ronald B. Schwadron

For: TGF BETA 1 INHIBITOR PEPTIDES

Mail Stop Sequence Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

## SUBMISSION OF "SEQUENCE LISTING," COMPUTER READABLE COPY, AND/OR AMENDMENT PERTAINING THERETO FOR BIOTECHNOLOGY INVENTION CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE

#### CERTIFICATION UNDER 37 C.F.R. 1.8(a) and 1.10\*

(When using Express Mail, the Express Mail label number is mandatory; Express Mail certification is optional.)

I hereby certify that, on the date shown below, this correspondence is being:

#### **MAILING**

	· - ·	
Ø	deposited with the United States Postal Service in an envelope addr Alexandria, VA 22313-1450.	ressed to the Commissioner for Patents, P. O. Box 1450,
	37 C.F.R. 1.8(a)	37 C.F.R. 1.10*
Ø	with sufficient postage as first class mail.	as "Express Mail Post Office to Address"  Mailing Label No
□ Da	Date: October 19, 2004	
*W.	WARNING: Each paper or fee filed by "Express Mail" must have the thereon prior to mailing, 37 C.F.R. 1.10(b). "Since the filing of correspondence under § 1.10 without that can be avoided by the exercise of reasonable care granted on petition." Notice of Oct. 24, 1996, 60 Fed. Fed. Fed. Fed. Fed. Fed. Fed. Fed.	ne number of the "Express Mail" mailing label placed the Express Mail mailing label thereon is an oversight to, requests for waiver of this requirement will <b>not</b> be

1.	[ X ]	This re	plies to the C	Office Letter date	d September 20, 2004	
----	-------	---------	----------------	--------------------	----------------------	--

NOTE: If these papers are filed before the office letter issues, adequate identification of the original papers should be made, e.g., in addition to the name of the inventor and title of invention, the filing date based on the "Express Mail" procedure, the serial number from the return post card or the attorney's docket number added.

[x] A copy of the Office Letter is enclosed.

#### IDENTIFICATION OF PERSON MAKING STATEMENT

2.	I,	CLIFFORD J. MASS
		(type or print name of person signing below)

state the following:

#### ITEMS BEING SUBMITTED

3. Submitted herewith is/are

(check each item as applicable)

- A. [X] "Sequence Listing(s)" for the nucleotide and/or amino acid sequence(s) in this application. Each "Sequence Listing" is assigned a separate identifier as required in 37 C.F.R. 1.821(c) and 37 C.F.R. 1.822 and 1.823.
- B. [X] An amendment to the description and/or claims, wherein reference is made to the sequence by use of the assigned identifier, as required in 37 C.F.R. 1.821(d).
- C. [X] A copy of each "Sequence Listing" submitted for this application in computer readable form, in accordance with the requirements of 37 C.F.R. 1.821(e) and 1.824.
- D. [] Please transfer to this application, in accordance with 37 C.F.R. 1.821(e), the computer readable copy(ies) from applicant's other application identified as follows:

(Submission-Nucleotide and/or Amino Acid Sequence—page 2 of 6) 9-37

S	lication of: Serial No.: Filed: For:	Group No.: Examiner:
	nputer readable form(s) of applicant's other entifier(s)" of this application as follows:	er application corresponds or compares to the
Computer Re (other application)		"Sequence Identifier" (this application)
applic reada be acc	ation of the applicant on file in the Office, referent ble form in lieu of filing a duplicate computer readab	be identical with the computer readable form of another ce may be made to the other application and computer le form in the new application. The new application shall er application and computer readable form, both of which
E. [X]	A statement that the content of each "Se eadable copy are the same, as required in 3	equence Listing" submitted and each computer 7 C.F.R. 1.821(f).
[	Because the statement is not made by a the Statement is verified as required in	person registered to practice before the Office, 37 C.F.R. 1.821(b).
F. [X]	Because this submission is made in fulfil a statement that the submission includes	lling the requirement under 37 C.F.R. 1.821(g), s no new matter.
. [	Because the statement is not made by a the statement is verified, as required in	person registered to practice before the Office, 37 C.F.R. 1.821(g).
A	STATEMENT THAT "SEQ AND COMPUTER READABLE ( ND/OR THAT PAPERS SUBMITTED I	COPY ARE THE SAME
4. I hereby s	state:	
	(complete applicable ite	m A and/or B)
A. [X]		ed in this application, including those forms icant's other application, is the same as the ted to relate.
	all papers accompanying this submission, or ther application, introduce no new matter.	for which a request for transfer from applicants'

4.

## **STATUS**

	SIAIOS
5.	Applicant is
	X ] a small entity:
	] other than a small entity.
	EXTENSION OF TERM
6. NOT	37 C.F.R. § 1.704(b)" an applicant shall be deemed to have failed to engage in reasonable efforts to conclude processing or examination of an application for the cumulative total of any periods of time in excess of three month that are taken to reply to any notice or action by the Office making any rejection, objection, argument, or other equest, measuring such three-month period from the date the notice or action was mailed or given to the applican in which case the period of adjustment set forth in § 1.703 shall be reduced by the number of days, if any, beginning on the day after the date that is three months after the date of mailing or transmission of the Office communication notifying the applicant of the rejection, objection, argument, or other request and ending on the date the reply was filed. The period, or shortened statutory period, for reply that is set in the Office action or notice has no effect on the three-month period set forth in this paragraph."
NOT	: "Extension of Time in Patent Cases (Supplement Amendments) If a timely and complete response has been filed afte a Non-Final Office Action, an extension of time is not required to permit filing and/or entry of an additiona amendment after expiration of the shortened statutory period.
	If a timely response has been filed after a Final Office Action, an extension of time is required to permit filing and/o entry of a Notice of Appeal or filing and/or entry of an additional amendment after expiration of the shortenes statutory period unless the timely-filed response placed the application in condition for allowance. Of course, if Notice of Appeal has been filed within the shortened statutory period, the period has ceased to run." Notice of Dec. 10 1985 (1061 O.G. 34-35).
NOT	See 37 C.F.R. 1.645 for extensions of time in interference proceedings and 37 C.F.R. 1.550(c) for extensions of time in reexamination proceedings.
7.	The proceedings herein are for a patent application and the provisions of 37 C.F.R. 1.136 apply.
	(complete (a) or (b) as applicable)
	a) [ ] Applicant petitions for an extension of time under 37 C.F.R. 1.136 (fees: 37 C.F.R 1.17(a)(1)-(4)) for the total number of months checked below:
	Extension Fee for other than Fee for months small entity small entity
	[ ] one month \$110.00 \$55.00 [ ] two months \$430.00 \$215.00

If an additional extension of time is required, please consider this a petition therefor.

\$980.00

\$1,530.00

[ ] three months

[ ] four months

Fee \$ \_\_\_\_\_

\$490.00

\$765.00

			(check and complete the next item, if applicable)
		[]	An extension for months has already been secured, and the fee paid therefor of \$ is deducted from the total fee due for the total months of extension now requested.
			Extension fee due with this request \$
			OR
	(b)	[X]	Applicant believes that no extension of term is required. However, this conditional petition is being made to provide for the possibility that applicant has inadvertently overlooked the need for a petition and fee for extension of time.
			FEE PAYMENT
8.	[]	Attache	ed is a check in the sum of \$
	[]		Account No the sum of \$ icate of this transmittal is attached.
			FEE DEFICIENCY
9. <i>NO</i>	TE:	the addit before the to charge to apply t	s a fee deficiency and there is no authorization to charge an account, additional fees are necessary to cover ional time consumed in making up the original deficiency. If the maximum, six-month period has expired e deficiency is noted and corrected, the application is held abandoned. In those instances where authorization is included, processing delays are encountered in returning the papers to the PTO finance Branch in order these charges prior to action on the cases. Authorization to charge the deposit account for any fee deficiency is checked. See the Notice of April 7, 1986, 1065 O.G. 31-33.

10. [X] If any additional extension and/or fee is required, charge Account No. 12-0425.

## SIGNATURE(s)

	CLIFFORD J-MASS
	(type or print name sperson signing statement)
0 4 1 10 2004	Signature///
October 19, 2004 Date	
Date	
P.O. Address of Signatory	$\mathcal{G}$
1.0. Address of Signatory	-
c/o Ladas & Parry LLP 26 West 61 <sup>st</sup> Street New York, N.Y. 10023	
	[ ] Inventor
(If applicable)	<ul><li>[ ] Assignee of complete interest</li><li>[ ] Person authorized to sign on behalf of assignee</li></ul>
Tel. No.: ( )	[X] Practitioner of record
Reg. No.	[ ] Filed under Rule 34(a)
	[ ] Registration No
	(specify identity of person signing)
(type name of assignee)	lowing, if applicable)
Address of assignee	
Title of person authorized to sign on behalf of assignee	
A "STATEMENT UNDER 37 C.F.R. 3.73(b)" is	attached.
Assignment recorded in PTO onReel Frame	SIGNATURE OF PRACTITIONER
Reg. No.	(type or print name of practitioner)
Tel. No.: ( )	P.O. Address
	c/o Ladas & Parry LLP 26 West 61 <sup>st</sup> Street New York, N.Y. 10023

Customer No.:

00140

PATENT TRADEMARK OFFICE



# **Notice to Comply**

Application No.
09/831253

Examiner

Ron Schwadron,
Ph.D.

Applicant(s)

Ezaverro Saewz et al.

Art Unit
1644

# NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

provisions of 37 CFR 1.136(a)).
The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):
1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
7. Other: see enclosed communication
Applicant Must Provide:  An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).
For questions regarding compliance to these requirements, please contact:
For Rules Interpretation, call (703) 308-4216 or (703) 308-2923 For CRF Submission Help, call (703) 308-4212 or 308-2923 PatentIn Software Program Support
Technical Assistance703-287-0200 To Purchase PatentIn Software703-306-2600
PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY